In 2024, "illness, addiction, or accident" has become the most common cause of private over-indebtedness in Germany for the first time, as current data from the Federal Statistical Office (DESTATIS) shows. With a share of 18.1 percent, this factor precedes unemployment, which ranks at 17.4 percent. Experts from the University of Witten/Herdecke consider this an alarming signal and call for more research and targeted prevention measures to protect those affected from the financial consequences of serious illnesses at an early stage. The development highlights a growing societal challenge that healthcare, politics, and science must address together. The figures mark a historic turning point, as illness is for the first time since the beginning of official surveys the leading cause of over-indebtedness. "A serious illness affects many people twice: health-wise and financially," explains Prof. Dr. Eva Münster, holder of the professorship for General Practice Healthcare Research in Vulnerable Population Groups at the Institute for General Practice and Outpatient Healthcare at the University of Witten/Herdecke. "The associated… 

A study by the Max Planck Institute for Biological Intelligence, published in Nature Neuroscience, shows how inhibitory neurons in the brains of mice accelerate their development to ensure neural balance. Later-forming inhibitory neurons mature faster than those that form earlier, catching up to their temporal deficit. This prevents an imbalance in the network that could lead to excessive or weak connections. Researchers led by Dr. Christian Mayer discovered that this accelerated maturation is controlled by genetic mechanisms that regulate access to genetic information via the chromatin landscape. Disruptions in these processes could favor developmental disorders such as autism or epilepsy. The findings offer insights into brain development and could provide approaches for researching neurological diseases. Furthermore, the study underscores the importance of “developmental timing.” In humans, where brain maturation takes longer, this could enable more complex networks and cognitive abilities. Further research is needed to understand the…

A research team led by Prof. Dr. Matthias Hardtke-Wolenski at the Hannover Medical School (MHH) is developing an innovative CAR T-cell therapy that suppresses excessive immune reactions in autoimmune diseases such as autoimmune hepatitis, multiple sclerosis, and diabetes. Unlike conventional CAR T-cells, which destroy disease-causing cells, the so-called regulatory T-cells (CAR-Tregs) use a biotechnological navigation system to protect target cells and specifically dampen inflammation. Five different CAR-Treg constructs have been developed and patented, and their effectiveness has so far been demonstrated in animal models and cell cultures. A clinical study for human application is in preparation. The newly developed antigen receptors (CARs) were precisely designed for specific disease patterns by identifying antibodies using antibody phage display, a method optimized at the Institute of Biochemistry, Biotechnology and Bioinformatics at TU Braunschweig. "Our CAR-Tregs act like a brake against misguided immune reactions without attacking healthy cells," explains Prof. Hardtke-Wolenski. One advantage: Even in the event of navigation errors, the risk remains… 

The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Adcentrx Therapeutics' ADRX-0405 for the treatment of gastric cancer. ADRX-0405, a STEAP1 protein-targeting antibody-drug conjugate (ADC), is currently being investigated in a Phase 1a/b study (NCT06710379) for advanced solid tumors, including gastric cancer. "The Orphan Drug Designation is a significant milestone for Adcentrx and underscores the potential of ADRX-0405 to improve the lives of gastric cancer patients," said Dr. Hui Li, Founder and CEO of Adcentrx. The designation encourages the development of therapies for rare diseases affecting fewer than 200,000 people in the U.S., offering benefits such as tax credits and potential market exclusivity. Gastric cancer, which the American Cancer Society projects will cause approximately 30,300 new cases in the U.S. in 2025, is often diagnosed at advanced stages. ADRX-0405 utilizes Adcentrx's i-Conjugation® technology, which enables a stable ADC with a drug-antibody ratio of eight (DAR 8)... nbsp;